Drug Profile

MMV 052

Alternative Names: MMV052; OZ 609

Latest Information Update: 28 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Medicines for Malaria Venture; Monash University; Swiss Tropical and Public Health Institute; University of Nebraska
Developer Medicines for Malaria Venture
Class Antimalarials; Peroxides; Piperidines; Spiro compounds
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Feb 2023 No recent reports of development identified for preclinical development in Malaria in Switzerland (PO)
01 Feb 2019 Chemical structure information added
28 Jan 2019 Medicines for Malaria Venture plans a first-in-human trial in Malaria in 4Q 2019

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com